Tan Li

Founder presso SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

Patrimonio netto: 471 M $ in data 31/03/2024

60 anni

100 relazioni

Health Technology

Consumer Services

Distribution Services

Profilo

Tan Li ha fondato la Shenzhen Hepalink Pharmaceutical Group Co. La signora Li è direttore esecutivo e vice direttore generale di questa società e partner esecutivo di Urumqi Jintiantu Equity Investment Partnership LP. La signora Li è anche nel consiglio di amministrazione di Kymab Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. e Kymab Group Ltd. Si è laureata presso l'Università di Sichuan.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. CLASS A 32.72%	30/06/2023	408 041 280 ( 32.72% )	471 M $	31/03/2024

Posizioni attive di Tan Li

Società	Posizione	Inizio
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	Founder	21/04/1998
Urumqi Jintiantu Equity Investment Partnership LP	Corporate Officer/Principal	09/08/2013
Shenzhen Techdow Pharmaceutical Co., Ltd.	Director/Board Member	-
Shenzhen Duopule Industrial Development Co., Ltd. Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.	Director/Board Member	13/01/2014
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Director/Board Member	-
Kymab Group Ltd. Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.	Director/Board Member	20/01/2017

Tutte le posizioni attive di Tan Li

Formazione di Tan Li

Sichuan University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Tan Li

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	Health Technology

Aziende private	5
Urumqi Jintiantu Equity Investment Partnership LP
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Health Technology
Shenzhen Techdow Pharmaceutical Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.	Distribution Services
Kymab Group Ltd. Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.	Health Technology

Vedi le connessioni aziendali